Gossamer Bio's PROSERA Phase 3 Misses Primary Endpoint, Q1 Losses Widen to $46.66M
GOSS is trading near its 52-week low of $0.314 (6.0% above the low) on light trading volume (0.3× avg).
Summary
Gossamer Bio reported Q1 2026 results with revenue of $16.96M, but a net loss of $46.66M and EPS of ($0.20), representing a significant increase in losses year-over-year. Critically, the Phase 3 PROSERA trial for seralutinib, while showing a numerical improvement, *missed its prespecified alpha*, indicating it did not meet its primary statistical endpoint. The company also announced a narrowed pipeline focus to pulmonary arterial hypertension (PAH) with a planned NDA submission in September 2026, and paused enrollment in its PH-ILD Phase 3 trial.
This clinical setback is highly material, especially following the company's previous 10-K filing which disclosed a going concern warning, a prior failed Phase 3 trial, and significant workforce reductions. Missing the primary endpoint in a Phase 3 trial for a key drug significantly jeopardizes its path to regulatory approval and commercialization, adding to the company's already precarious financial and operational situation. The widening losses and strategic pipeline narrowing, coupled with limited liquidity into Q1 2027, underscore increased execution risk.
Investors will closely monitor any further communication regarding the PROSERA trial and FDA engagement, as well as progress towards the planned PAH NDA submission. The company's ability to secure additional financing will be critical given its current cash runway.
At the time of this announcement, GOSS was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.31 to $3.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.